AVE 0991
目录号 : GC12065
A Mas receptor agonist
Cas No.:304462-19-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Kinase experiment [1]: | |
|
Preparation Method |
Competition experiments with increasing concentrations of AVE 0991 and unlabeled Ang-(1 7) were performed in the presence of 10 nmol/L [125I]-Ang-(1-7). Assays were terminated by vacuum filtration ( 15 mm Hg) over Durapore filters (0.65 ¦̭, Opak 96-well plates, Millipore) presoaked with 1% BSA. |
|
Applications |
AVE 0991 and unlabeled Ang-(1-7) competed the specific binding of [125I]-Ang-(1-7), with IC50 values of 21 ¡À35 and 220 ¡À 280 nmol/L, respectively (each n=3). The Ang-(1-7) analogue [D-Ala7]-Ang-(1 7) totally competed the specific binding of [125I]-Ang-(1-7), with an IC50 value of 0.41 ¡À3.0 ¦̭ol/L (n=3). |
| Cell experiment [2]: | |
|
Cell lines |
Chinese hamster ovary (CHO) cells |
|
Preparation Method |
Binding of rhodamine Ang-(1-7) in Mas-transfected CHO cells was performed under similar conditions using 2*10 -9 mol/L rhodamine-labeled Ang-(1-7) in the presence or absence of AVE 0991(10 -6 mol/L), CV11974, or PD123319 |
|
Reaction Conditions |
AVE 0991 (10-6 mol/L) |
|
Applications |
AVE 0991 displaced the binding of 125I-Ang-(1-7) in Mas-transfected monkey kidney cells (COS) cells (IC50=4.75x10(-8) mol/L) and of rhodamine-Ang-(1-7) in Mas-transfected Chinese hamster ovary (CHO) cells. It also produced NO release in Mas-transfected CHO cells blocked by A-779 but not by angiotensin II type-1 (AT1) and AT2 antagonists. |
| Animal experiment [3]: | |
|
Animal models |
Male C57BL/6J mice (8¨C10 weeks old; 24¨C26 g) |
|
Preparation Method |
Twenty-four h after ligation, the surviving mice were randomly divided into four groups: 1) sham-operated group, 2) vehicle-treated AB group (vehicle-treated group ), 3) AB mice treated with AVE 0991 ( AVE 0991 group ). AVE 0991 group was administered orally once a day at AVE 0991 (20 mg kg/day) for 4 weeks while isovolumic sodium chloride was administrated in the same manner for the sham-operated and vehicle-treated group. |
|
Dosage form |
AVE 0991 (20 mg kg/day) for 4 weeks |
|
Applications |
AVE 0991 treatment could attenuate cardiac hypertrophy and improve heart function, which may be due to reduce oxidative stress./p> |
|
References: [1]. Wiemer G, Dobrucki LW,et,al. AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension. 2002 Dec;40(6):847-52. doi: 10.1161/01.hyp.0000037979.53963.8f. PMID: 12468568. [2]. Pinheiro SV, Sim?es e Silva AC, et,al.Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension. 2004 Oct;44(4):490-6. doi: 10.1161/01.HYP.0000141438.64887.42. Epub 2004 Aug 23. PMID: 15326087. [3]. Ma Y, Huang H, et,al. AVE 0991 attenuates cardiac hypertrophy through reducing oxidative stress. Biochem Biophys Res Commun. 2016 Jun 10;474(4):621-625. doi: 10.1016/j.bbrc.2015.09.050. Epub 2015 Sep 25. PMID: 26403967. |
|
AVE 0991 is a Nonpeptide Mimic of the Effects of Angiotensin-(1-7) on the Endothelium. AVE 0991 and unlabeled Ang-(1-7) competed for high-affinity binding of [125I]-Ang-(1-7) to bovine aortic endothelial cell membranes with IC50 values of 21+/-35 and 220+/-280 nM, respectively[4].
AVE 0991 displaced the binding of 125I-Ang-(1-7) in Mas-transfected monkey kidney cells (COS) cells (IC50=4.75x10(-8) mol/L) and of rhodamine-Ang-(1-7) in Mas-transfected Chinese hamster ovary (CHO) cells. It also produced NO release in Mas-transfected CHO cells blocked by A-779 but not by angiotensin II type-1 (AT1) and AT2 antagonists[7].
AVE 0991 attenuates oxidative stress and neuronal apoptosis via Mice were underwent aortic banding to induce cardiac hypertrophy followed by the administration of AVE 0991 (20 mg kg.day (-1)) for 4 weeks. It was shown that AVE 0991 reduced left ventricular hypertrophy and improved heart function, characterized by decreases in left ventricular weight and left ventricular end-diastolic diameter, and increases in ejection fraction. Moreover, AVE 0991 significantly down-regulated mean myocyte diameter and attenuate the gene expression of the hypertrophic markers[2].Mas/PKA/CREB/UCP-2 pathway after subarachnoid hemorrhage in rats[1]. Enhanced Ang II and attenuated Ang-(1-7) levels were also observed in the liver tissue of heatstroke rats, which were consistent with their receptors and converting enzymes. Hepatic damage associated with increased ROS and protein expression levels of NOX4, NLRP3, caspase-1, and IL-1β was attenuated by AVE 0991, an analogue of Ang-(1-7) [3]. Oral treatment with AVE 0991 reduces blood-pressure cardiac remodeling and improves baroreflex sensitivity in 2K1C renovascular hypertensive rats[5]. AVE 0991 prevented AngII-inducing myocardial hypertrophy in a dose-dependent fashion, a process that may be associated with the inhibition of TGF-beta1/Smad2 signaling[6].
References:
[1]. Mo J, Enkhjargal B, et,al. AVE 0991 attenuates oxidative stress and neuronal apoptosis via Mas/PKA/CREB/UCP-2 pathway after subarachnoid hemorrhage in rats. Redox Biol. 2019 Jan;20:75-86. doi: 10.1016/j.redox.2018.09.022. Epub 2018 Sep 28. PMID: 30296700; PMCID: PMC6174866.
[2]. Ma Y, Huang H, et,al. AVE 0991 attenuates cardiac hypertrophy through reducing oxidative stress. Biochem Biophys Res Commun. 2016 Jun 10;474(4):621-625. doi: 10.1016/j.bbrc.2015.09.050. Epub 2015 Sep 25. PMID: 26403967.
[3]. Zhang M, Zhu X, et,al. AVE 0991 Attenuates Pyroptosis and Liver Damage after Heatstroke by Inhibiting the ROS-NLRP3 Inflammatory Signalling Pathway. Biomed Res Int. 2019 Aug 19;2019:1806234. doi: 10.1155/2019/1806234. PMID: 31531346; PMCID: PMC6720052.
[4]. Wiemer G, Dobrucki LW, et,al. AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension. 2002 Dec;40(6):847-52. doi: 10.1161/01.hyp.0000037979.53963.8f. PMID: 12468568.
[5]. Cunha TM, Lima WG, et,al.The nonpeptide ANG-(1-7) mimic AVE 0991 attenuates cardiac remodeling and improves baroreflex sensitivity in renovascular hypertensive rats. Life Sci. 2013 Mar 12;92(4-5):266-75. doi: 10.1016/j.lfs.2012.12.008. Epub 2013 Jan 16. PMID: 23333828.
[6]. He JG, Chen SL, et,al. The nonpeptide AVE0991 attenuates myocardial hypertrophy as induced by angiotensin II through downregulation of transforming growth factor-beta1/Smad2 expression. Heart Vessels. 2010 Sep;25(5):438-43. doi: 10.1007/s00380-009-1213-7. Epub 2010 Jul 31. PMID: 20676968.
[7]. Pinheiro SV, SimÕes e Silva AC, et,al. Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension. 2004 Oct;44(4):490-6. doi: 10.1161/01.HYP.0000141438.64887.42. Epub 2004 Aug 23. PMID: 15326087.
AVE 0991 是血管紧张素 (1-7) 对内皮细胞作用的非肽模拟物。 AVE 0991 和未标记的 Ang-(1-7) 竞争 [125I]-Ang-(1-7) 与牛主动脉内皮细胞膜的高亲和力结合，IC50 值为 21+/-35 和 220+/-280 nM，分别[4].
AVE 0991 在 Mas 转染的猴肾细胞 (COS) 细胞中取代了 125I-Ang-(1-7) 的结合 (IC50=4.75x10 (-8) mol/L) 和罗丹明-Ang-(1-7) 在 Mas 转染的中国仓鼠卵巢 (CHO) 细胞中。它还在被 A-779 而不是血管紧张素 II 型 1 (AT1) 和 AT2 拮抗剂阻断的 Mas 转染的 CHO 细胞中产生 NO 释放[7]。
AVE 0991减轻氧化应激和神经元凋亡，通过对小鼠进行主动脉束带以诱导心脏肥大，然后给予 AVE 0991（20 mg kg.day (-1)）4 周。结果表明，AVE 0991 减少了左心室肥大并改善了心脏功能，其特点是左心室重量和左心室舒张末期直径减少，射血分数增加。此外，AVE 0991显着下调平均肌细胞直径并减弱肥大标志物的基因表达[2].大鼠蛛网膜下腔出血后Mas/PKA/CREB/UCP-2通路[ 1]。在中暑大鼠的肝组织中也观察到增强的 Ang II 和减弱的 Ang-(1-7) 水平，这与其受体和转化酶一致。与 ROS 和 NOX4、NLRP3、caspase-1 和 IL-1β 蛋白表达水平升高相关的肝损伤；被 AVE 0991 减弱，AVE 0991 是 Ang-(1-7) [3] 的类似物。口服 AVE 0991 可降低 2K1C 肾血管性高血压大鼠的血压心脏重塑并提高压力反射敏感性[5]。 AVE 0991 以剂量依赖性方式阻止 AngII 诱导的心肌肥大，这一过程可能与抑制 TGF-beta1/Smad2 信号转导有关[6]。
| Cas No. | 304462-19-9 | SDF | |
| 化学名 | 1-ethyl-3-[3-[4-[(5-formyl-4-methoxy-2-phenylimidazol-1-yl)methyl]phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylurea | ||
| Canonical SMILES | CCNC(=O)NS(=O)(=O)C1=C(C=C(S1)CC(C)C)C2=CC=C(C=C2)CN3C(=C(N=C3C4=CC=CC=C4)OC)C=O | ||
| 分子式 | C29H32N4O5S2 | 分子量 | 580.72 |
| 溶解度 | ≥ 29.036mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.722 mL | 8.61 mL | 17.22 mL |
| 5 mM | 0.3444 mL | 1.722 mL | 3.444 mL |
| 10 mM | 0.1722 mL | 0.861 mL | 1.722 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
AVE 0991 attenuates oxidative stress and neuronal apoptosis via Mas/PKA/CREB/UCP-2 pathway after subarachnoid hemorrhage in rats
Oxidative stress and neuronal apoptosis have been demonstrated to be key features in early brain injury (EBI) after subarachnoid hemorrhage (SAH). Previous studies have indicated that Mas receptor activation initiates an anti-oxidative and anti-apoptotic role in the brain. However, whether Mas activation can attenuate oxidative stress and neuronal apoptosis after SAH remains unknown. To investigate the beneficial effect of Mas on oxidative stress injury and neuronal apoptosis induced by SAH, a total of 196 rats were subjected to an endovascular perforation model of SAH. AVE 0991 (AVE), a selective agonist of Mas, was administered intranasally 1 h after SAH induction. A779, a selective inhibitor of Mas, and small interfering ribonucleic acid (siRNA) for UCP-2 were administered by intracerebroventricular (i.c.v) injection at 1 h and 48 h before SAH induction respectively. Neurological tests, immunofluorescence, TUNEL, Fluoro-Jade C, DHE staining, and Western blot experiments were performed. We found that Mas activation with AVE significantly improved neurobehavioral scores and reduced oxidative stress and neuronal apoptosis in SAH+AVE group compared with SAH+vehicle group. Moreover, AVE treatment significantly promoted phosphorylation of CREB and the expression UCP-2, as well as upregulated expression of Bcl-2 and downregulation of Romo-1 and Bax. The protective effects of AVE were reversed by i.c.v injection of A779 and UCP-2 siRNA in SAH+AVE+A779 and SAH+AVE+UCP-2 siRNA groups, respectively. In conclusion, our data provides evidence that Mas activation with AVE reduces oxidative stress injury and neuronal apoptosis through Mas/PKA/p-CREB/UCP-2 pathway after SAH. Furthermore, our study indicates that Mas may be a novel therapeutic treatment target in early brain injury of SAH.
AVE 0991 attenuates cardiac hypertrophy through reducing oxidative stress
AVE 0991, the nonpeptide angiotensin-(1-7) (Ang-(1-7)) analog, is recognized as having beneficial cardiovascular effects. However, the mechanisms have not been fully elucidated. This study was designed to investigate the effects of AVE 0991 on cardiac hypertrophy and the mechanisms involved. Mice were underwent aortic banding to induce cardiac hypertrophy followed by the administration of AVE 0991 (20 mg kg﹞day (-1)) for 4 weeks. It was shown that AVE 0991 reduced left ventricular hypertrophy and improved heart function, characterized by decreases in left ventricular weight and left ventricular end-diastolic diameter, and increases in ejection fraction. Moreover, AVE 0991 significantly down-regulated mean myocyte diameter and attenuate the gene expression of the hypertrophic markers. Furthermore, AVE 0991 inhibited the expression of NOX 2 and NOX 4, meaning that AVE 0991 reduced oxidative stress of cardiac hypertrophy mice. Our data showed that AVE 0991 treatment could attenuate cardiac hypertrophy and improve heart function, which may be due to reduce oxidative stress.
AVE 0991 Suppresses Astrocyte-Mediated Neuroinflammation of Alzheimer's Disease by Enhancing Autophagy
Purpose: Our previous study has shown that AVE 0991, a nonpeptide analogue of Ang-(1-7), ameliorates cognitive decline and inhibits NLRP3 inflammasome of astrocytes in Alzheimer's disease model mice. Additionally, several studies have suggested that activation of autophagy appears to effectively inhibit the progression of neuroinflammation. However, it is unclear whether AVE 0991 can modulate astrocyte autophagy to suppress neuroinflammation in Alzheimer's disease.
Materials and methods: APP/PS1 mice and A汕-treated primary astrocytes were used as the research objects in vivo and in vitro, respectively. Water maze test was used to evaluate cognitive function of mice, Nissl staining and immunofluorescence staining was used to assess neuronal damage. ELISA kits were used to detect the levels of Ang-(1-7) and A汕 in the cortex, and qRT-PCR was used to detect the expression of cortical inflammation-related mediators. The expression of autophagy-related proteins in cortex were detected by Western blot. The upstream molecular responses involved in inflammation inhibition by AVE 0991 were validated by means of using the Mas1 antagonist and autophagy inhibitor.
Results: We found that 30 days of intraperitoneal administration of AVE 0991 improved. A汕 deposition, neuronal death, and cognitive deficits in APP/PS1 Alzheimer's disease model mice. Moreover, AVE 0991 treatment greatly suppressed astrocyte-mediated inflammation and up-regulated the expression of autophagy. Furthermore, the inhibitory effect of AVE 0991 on the expression of inflammatory factors was reversed by 3-MA, an autophagy inhibitor.
Conclusion: These findings suggest that regulation of autophagy is critical for inhibiting astrocyte neuroinflammatory responses and demonstrate a potential neuroprotective mechanism by which AVE 0991 could suppress neuroinflammatory responses by enhancing autophagy.
AVE 0991, a non-peptide Mas-receptor agonist, facilitates penile erection
The renin-angiotensin system plays a crucial role in erectile function. It has been shown that elevated levels of angiotensin II contribute to the development of erectile dysfunction both in humans and in aminals. On the contrary, the heptapeptide angiotensin-(1-7) appears to mediate penile erection by activation of the Mas receptor. Recently, we have shown that the erectile function of Mas gene-deleted mice was substantially reduced, which was associated with a marked increase in fibrous tissue in the corpus cavernosum. We have hypothesized that the synthetic non-peptide Mas agonist, AVE 0991, would potentiate penile erectile function. We showed that intracavernosal injection of AVE 0991 potentiated the erectile response of anaesthetized Wistar rats, measured as the ratio between corpus cavernosum pressure and mean arterial pressure, upon electrical stimulation of the major pelvic ganglion. The facilitatory effect of AVE 0991 on erectile function was dose dependent and completely blunted by the nitric oxide synthesis inhibitor, l-NAME. Importantly, concomitant intracavernosal infusion of the specific Mas receptor blocker, A-779, abolished the effect of AVE 0991. We demonstrated that AVE 0991 potentiates the penile erectile response through Mas in an NO-dependent manner. Importantly, these results suggest that Mas agonists, such as AVE 0991, might have significant therapeutic benefits for the treatment of erectile dysfunction.
AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium
Recently, we demonstrated that the heptapeptide angiotensin-(1-7) (Ang-[1-7]) exhibits a favorable kinetic of nitric oxide (NO) release accompanied by extremely low superoxide (O2-) production. In this report we describe AVE 0991, a novel nonpeptide compound that evoked effects similar to Ang-(1-7) on the endothelium. AVE 0991 and unlabeled Ang-(1-7) competed for high-affinity binding of [125I]-Ang-(1-7) to bovine aortic endothelial cell membranes with IC50 values of 21+/-35 and 220+/-280 nmol/L, respectively. Stimulated NO and O2- release from bovine aortic endothelial cells was directly and simultaneously measured on the cell surface by selective electrochemical nanosensors. Peak concentrations of NO and O2- release by AVE 0991 and Ang-(1-7) (both 10 micromol/L) were not significantly different (NO: 295+/-20 and 270+/-25 nmol/L; O2-: 18+/-2 and 20+/-4 nmol/L). However, the released amount of bioactive NO was approximately 5 times higher for AVE 0991 in comparison to Ang-(1-7). The selective Ang-(1-7) antagonist [D-Ala(7)]-Ang-(1-7) inhibited the AVE 0991-induced NO and O2- production by approximately 50%. A similar inhibition level was observed for the Ang II AT1 receptor antagonist EXP 3174. In contrast, the Ang II AT2 receptor antagonist PD 123,177 inhibited the AVE 0991-stimulated NO production by approximately 90% but without any inhibitory effect on O2- production. Both NO and O2- production were inhibited by NO synthase inhibition ( approximately 70%) and by bradykinin B2 receptor blockade (approximately 80%). AVE 0991 efficiently mimics the effects of Ang-(1-7) on the endothelium, most probably through stimulation of a specific, endothelial Ang-(1-7)-sensitive binding site causing kinin-mediated activation of endothelial NO synthase.